calendar

4 catalysts · 2 phase 1 initiation · 1 phase 2 completion · 1 phase 2 initiation

★ save view ↓export CSV

next 91 dayslessmore

MonWedFri

view

agenda month

sort

soonest latest type sponsor alpha

TA: immunology×from 2026-04-28×to 2026-04-28×clear all

type

phase 1 initiation2
phase 2 completion1
phase 2 initiation1

therapy area

Infectious Disease13
Oncology9

Immunology

Week of Apr 27, 2026

›Apr 28, 2026phase 1 initiation105d agoShanghai Argo Pharmaceutical Co Ltd — BW-20805 (Phase I Trial Initiation)BW-20805

Therapy area: Immunology. Indication: Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

full page →BW-20805 →source: globaldata

›Apr 28, 2026phase 1 initiation105d agoShenzhen MagicRNA Biotech Co Ltd — HN-2302 (Phase I Trial Initiation)HN-2302

Therapy area: Immunology. Indication: Autoimmune Disorders, Diffuse Cutaneous Systemic Sclerosis, Systemic Sclerosis (Scleroderma)

full page →HN-2302 →source: globaldata

›Apr 28, 2026phase 2 completion105d agoInonu University — albumin gel- and platelet- rich fibrin (Phase II Trial Completion)albumin gel- and platelet- rich fibrin

Therapy area: Immunology, Mouth and Dental Disorders. Indication: Inflammation, Periodontal Disease, Periodontitis

full page →albumin gel- and platelet- rich fibrin →source: globaldata

›Apr 28, 2026phase 2 initiation105d agoTianjin Lisheng Pharmaceutical Co Ltd — dexamethasone acetate (Phase II Trial Initiation)dexamethasone acetate

Therapy area: Immunology, Respiratory. Indication: Allergic Rhinitis, Inflammation, Transplant Rejection

full page →dexamethasone acetate →source: globaldata